IL133585A0 - Soluble prodrugs of paclitaxel - Google Patents

Soluble prodrugs of paclitaxel

Info

Publication number
IL133585A0
IL133585A0 IL13358597A IL13358597A IL133585A0 IL 133585 A0 IL133585 A0 IL 133585A0 IL 13358597 A IL13358597 A IL 13358597A IL 13358597 A IL13358597 A IL 13358597A IL 133585 A0 IL133585 A0 IL 133585A0
Authority
IL
Israel
Prior art keywords
paclitaxel
onium salts
methods
novel
salts
Prior art date
Application number
IL13358597A
Other languages
English (en)
Original Assignee
Baker Norton Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baker Norton Pharma filed Critical Baker Norton Pharma
Publication of IL133585A0 publication Critical patent/IL133585A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Epoxy Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
IL13358597A 1997-06-20 1997-06-20 Soluble prodrugs of paclitaxel IL133585A0 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US1997/010746 WO1998058927A1 (en) 1997-06-20 1997-06-20 Soluble prodrugs of paclitaxel

Publications (1)

Publication Number Publication Date
IL133585A0 true IL133585A0 (en) 2001-04-30

Family

ID=22261122

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13358597A IL133585A0 (en) 1997-06-20 1997-06-20 Soluble prodrugs of paclitaxel

Country Status (10)

Country Link
EP (1) EP1001769B1 (xx)
JP (1) JP2002505682A (xx)
AT (1) ATE219363T1 (xx)
AU (1) AU3574097A (xx)
CA (1) CA2294606A1 (xx)
DE (1) DE69713526D1 (xx)
HU (1) HUP0002521A3 (xx)
IL (1) IL133585A0 (xx)
SK (1) SK182599A3 (xx)
WO (1) WO1998058927A1 (xx)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1171118A2 (en) * 1999-04-09 2002-01-16 Jessie L.S. Au Methods and compositions for enhancing delivery of therapeutic agents to tissues
US6380405B1 (en) 1999-09-13 2002-04-30 Nobex Corporation Taxane prodrugs
US6541508B2 (en) 1999-09-13 2003-04-01 Nobex Corporation Taxane prodrugs
US6713454B1 (en) 1999-09-13 2004-03-30 Nobex Corporation Prodrugs of etoposide and etoposide analogs
US6638906B1 (en) 1999-12-13 2003-10-28 Nobex Corporation Amphiphilic polymers and polypeptide conjugates comprising same
MXPA03006404A (es) * 2001-01-18 2004-12-02 Upjohn Co Composiciones quimioterapeuticas de microemulsion de paclitaxel con biodisponibilidad oral mejorada.
US7115565B2 (en) 2001-01-18 2006-10-03 Pharmacia & Upjohn Company Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability
US7351542B2 (en) 2002-05-20 2008-04-01 The Regents Of The University Of California Methods of modulating tubulin deacetylase activity
US20070172446A1 (en) 2003-05-16 2007-07-26 Intermune, Inc. Synthetic chemokine receptor ligands and methods of use thereof
US7597884B2 (en) 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
WO2006089209A2 (en) 2005-02-17 2006-08-24 The Board Of Trustees Of The Leland Stanford Junior University Txr1 and enhanced taxane sensitivity based on the modulation of a pathway mediated thereby
AU2008272785B2 (en) 2007-07-03 2014-06-12 Children's Hospital & Research Center At Oakland Polysialic acid derivatives, methods of production, and uses in enhancing cancer antigen production and targeting
WO2009143454A2 (en) 2008-05-22 2009-11-26 Kereos, Inc. Combination antitumor therapy
EP2310507A4 (en) 2008-07-08 2013-03-20 David Gladstone Inst METHODS AND COMPOSITIONS FOR MODULATING ANGIOGENESIS
WO2012137225A1 (en) * 2011-04-08 2012-10-11 Sphaera Pharma Pvt. Ltd Substituted methylformyl reagents and method of using same to modify physicochemical and/or pharmacokinetic properties of compounds
EP3539563A1 (en) 2012-07-19 2019-09-18 Redwood Bioscience, Inc. Antibody specific for cd22 and methods of use thereof
AU2013341711A1 (en) 2012-11-12 2015-05-21 Redwood Bioscience, Inc. Compounds and methods for producing a conjugate
ES2758227T3 (es) 2013-02-15 2020-05-04 Univ California Receptor de antígeno quimérico y métodos de uso del mismo
JP6410790B2 (ja) 2013-03-14 2018-10-24 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー ミトコンドリアアルデヒドデヒドロゲナーゼ−２調節因子およびその使用方法
CA2927806C (en) 2013-11-27 2023-01-10 Redwood Bioscience, Inc. Hydrazinyl-pyrrolo compounds and methods for producing a conjugate
US9879036B2 (en) 2014-02-19 2018-01-30 Aviv Therapeutics, Inc. Mitochondrial aldehyde dehydrogenase-2 binding compounds and methods of use thereof
EP3373977A4 (en) 2015-11-12 2019-07-17 The Board of Trustees of the Leland Stanford Junior University CELLULAR PENETRATION-RICH GUANIDINIC OLIGOPHOSPHOTRIESTERS FOR THE DELIVERY OF MEDICATION AND PROBE
EP3377523A4 (en) 2015-11-19 2019-06-19 The Regents of The University of California IMMUNITY CELL RECEIVERS REPRESSIBLE UNDER CONDITIONS AND METHODS OF USING THE SAME
EP3231421A1 (en) 2016-04-11 2017-10-18 Greenaltech, S.L. Uses of a carotenoid in the treatment or prevention of stress induced conditions
WO2017189432A1 (en) 2016-04-26 2017-11-02 R.P. Scherer Technologies, Llc Antibody conjugates and methods of making and using the same
MX2018014916A (es) 2016-06-01 2019-07-18 Servier Ip Uk Ltd Formulaciones de oxido de polialquileno-asparaginasa y metodos de preparacion y uso del mismo.
BR112019014615A2 (pt) 2017-01-18 2020-06-02 F1 Oncology, Inc. Receptores de antígeno quimérico contra axl ou ror2 e métodos de uso dos mesmos
EP3388082A1 (en) 2017-04-13 2018-10-17 Galera Labs, LLC Combination cancer immunotherapy with pentaaza macrocyclic ring complex
EA202091832A1 (ru) 2018-01-31 2021-01-11 ГАЛЕРА ЛЭБЗ, ЭлЭлСи Комбинированная терапия злокачественных новообразований макроциклическим кольцевым комплексом пентаазы и противоопухолевым агентом на основе платины
US11660266B2 (en) 2018-04-11 2023-05-30 Ohio State Innovation Foundation Methods and compositions for sustained release microparticles for ocular drug delivery
MX2021000644A (es) 2018-07-18 2021-08-19 Manzanita Pharmaceuticals Inc Conjugados para suministrar un agente contra el cancer a las celulas nerviosas, metodos de uso y metodos para la elaboracion de los mismos.
EP3946626A1 (en) 2019-04-02 2022-02-09 Kenjockety Biotechnology, Inc. Efflux pump-cancer antigen multi-specific antibodies and compositions, reagents, kits and methods related thereto
MX2022009355A (es) 2020-01-29 2022-09-02 Kenjockety Biotechnology Inc Anticuerpo anti-mdr1 y uso del mismo.
US20230212305A1 (en) 2020-06-04 2023-07-06 Kenjockety Biotechnology, Inc. Anti-abcg2 antibodies and uses thereof
EP4161564A1 (en) 2020-06-04 2023-04-12 Kenjockety Biotechnology, Inc. Abcg2 efflux pump-cancer antigen multi-specific antibodies and compositions, reagents, kits and methods related thereto
CA3193588A1 (en) 2020-09-02 2022-03-10 Kenjockety Biotechnology, Inc. Anti-abcc1 antibodies and uses thereof
CA3203652A1 (en) 2020-11-13 2022-05-19 William Robert ARATHOON Anti-mrp4 (encoded by abcc4 gene) antibodies and uses thereof
AU2022413942A1 (en) 2021-12-13 2024-05-30 William Robert Arathoon Living Trust Dated August 29, 2016 Anti-abcb1 antibodies
WO2023159220A1 (en) 2022-02-18 2023-08-24 Kenjockety Biotechnology, Inc. Anti-cd47 antibodies

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997015571A1 (en) * 1995-10-27 1997-05-01 The Scripps Research Institute Method for treating cancer using taxoid onium salt prodrugs
JP2002500667A (ja) * 1997-05-27 2002-01-08 ベーカー ノートン ファーマシューティカルズ インコーポレイテッド 人間の患者に対して経口的にタキサン類を投薬するための方法及び組成物

Also Published As

Publication number Publication date
DE69713526D1 (de) 2002-07-25
AU3574097A (en) 1999-01-04
ATE219363T1 (de) 2002-07-15
CA2294606A1 (en) 1998-12-30
EP1001769A1 (en) 2000-05-24
SK182599A3 (en) 2000-07-11
EP1001769B1 (en) 2002-06-19
JP2002505682A (ja) 2002-02-19
WO1998058927A1 (en) 1998-12-30
HUP0002521A2 (hu) 2001-06-28
EP1001769A4 (en) 2000-05-24
HUP0002521A3 (en) 2002-04-29

Similar Documents

Publication Publication Date Title
IL133585A0 (en) Soluble prodrugs of paclitaxel
HUT68498A (en) L-dopa ester compositions and process to prepare them
AU2002225772A1 (en) Therapeutic agents and methods of use thereof for treating an amyloidogenic disease
RU94045155A (ru) Способы ингибирования болезни альцгеймера
NZ516347A (en) Indanyl-substituted benzenecarboxamides, process for their preparation, their use as a medicament and pharmaceutical formulations containing them
MY125821A (en) Pharmaceutical composition of topiramate
DK0975595T3 (da) Kokainanaloger
AU9189301A (en) Use of substituted imidazo(1,2-A)pyridine-, imidazo(1,2-A)pyrimidine and imidazo(1,2-A)pyrazine-3-YL-amine derivatives for producing NOS-inhibiting medicaments
HUT47217A (en) Process for producing pharmaceutical compositions containing indol derivatives as active components
HUP0302635A2 (hu) Valpronsav foszfolipidszármazékai és ezek keveréke
PL342614A1 (en) Anticarcinogenic drugs
DE3480053D1 (en) A kit or device and method for administering gangliosides and derivatives thereof of inhalation and pharmaceutical compositions suitable therefor
IL136733A0 (en) Pharmaceutical composition containing sibutramine and orlistat
BG104983A (en) Aryl fused azapolycyclic compounds
TR200101163T2 (tr) Safra suyu ikameli fenil-alkenoilguanidinler, üretim yöntemleri, kullanımları
AU6826700A (en) Ceramide analogs, process for their preparation and their use as antitumor agents
BG106180A (en) Pharmaceutical composition containing sibutramine and orlistat
YU19302A (sh) 4-benzilaminohinolin konjugovan žučnom kiselinom i njegovi heteroanalozi, postupak za njihovu proizvodnju, lekovi koji sadrže ta jedinjenja i njihova primena
YU25202A (sh) Supstituisani piroli kao antiproliferativna sredstva za lečenje kancera
MY126998A (en) Substituted pyrroles.
BR9714774A (pt) Pró-drogas solúveis de paclitaxel
JO2360B1 (en) Substituted pyrolates
NO996311L (no) Loeselige forlegemidler av paklitaksel